Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors

Author(s): D. P. Zlotos

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 21 , 2012

Become EABM
Become Reviewer


The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.

Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 21 June, 2012
Page: [3532 - 3549]
Pages: 18
DOI: 10.2174/092986712801323153

Article Metrics

PDF: 45